Get the Stockscreener App
1.96
2.00%
-0.04
After Hours:
1.96
Heartbeam Inc stock is traded at $1.96, with a volume of 49,825.
It is down -2.00% in the last 24 hours and down -2.97% over the past month.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
See More
Previous Close:
$2.00
Open:
$1.96
24h Volume:
49,825
Relative Volume:
0.53
Market Cap:
$66.10M
Revenue:
-
Net Income/Loss:
$-14.47M
P/E Ratio:
-1.5806
EPS:
-1.24
Net Cash Flow:
$-12.19M
1W Performance:
+1.03%
1M Performance:
-2.97%
6M Performance:
-17.30%
1Y Performance:
-6.22%
1-Day Range:
$1.9401
$2.05
1-Week Range:
$1.85
$2.05
52-Week Range:
$1.70
$3.48
Heartbeam Inc Stock (BEAT) Company Profile
Name
Heartbeam Inc
Sector
Industry
Phone
408-899-4443
Address
2118 WALSH AVE., SUITE 210, SANTA CLARA
Compare BEAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
1.96 | 66.10M | 0 | -14.47M | -12.19M | -1.24 |
|
VEEV
Veeva Systems Inc
|
226.54 | 37.08B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
57.95 | 10.64B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
49.89 | 8.13B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
88.74 | 7.54B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.33 | 6.36B | 906.14M | -52.62M | 89.62M | -0.3621 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-20 | Initiated | Needham | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Aug-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-26-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-18 | Reiterated | Lake Street | Buy |
| Apr-26-18 | Reiterated | The Benchmark Company | Buy |
| Feb-23-18 | Reiterated | Dougherty & Company | Buy |
| Nov-08-17 | Reiterated | Dougherty & Company | Buy |
| Oct-26-17 | Initiated | Raymond James | Outperform |
| Oct-24-17 | Initiated | SunTrust | Buy |
| Aug-09-17 | Reiterated | Dougherty & Company | Buy |
| Jul-19-17 | Reiterated | The Benchmark Company | Buy |
| Apr-11-17 | Reiterated | Dougherty & Company | Buy |
| Dec-02-16 | Initiated | Dougherty & Company | Buy |
| Sep-13-16 | Initiated | Sidoti | Buy |
| Aug-03-16 | Reiterated | The Benchmark Company | Buy |
| Jul-28-15 | Reiterated | Dougherty & Company | Buy |
| Oct-24-13 | Initiated | The Benchmark Company | Buy |
| Aug-21-13 | Initiated | Dougherty & Company | Buy |
View All
Heartbeam Inc Stock (BEAT) Latest News
Benchmark maintains $8 target on Heartbeam stock post-Q4 report - Investing.com
Benchmark maintains $8 target on Heartbeam stock post-Q4 report By Investing.com - Investing.com South Africa
HeartBeam Announces Automated Cardiac Detection Patent Granted for HeartBeam AIMIGo™ System - Business Wire
HeartBeam reports net loss of USD 4.9M in Q4 2024 - Medical Buyer
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2024 Earnings Call Transcript - Insider Monkey
HeartBeam’s Earnings Call Highlights Strategic Progress - TipRanks
HeartBeam (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress - The Globe and Mail
HeartBeam Inc (BEAT) Q4 2024 Earnings Call Highlights: FDA Clearance and Strategic Moves By GuruFocus - Investing.com Canada
HeartBeam Advances Cardiac Care with FDA Clearance and New Innovations - TipRanks
Earnings call transcript: HeartBEAM Q4 2024 misses EPS forecasts - Investing.com
HeartBeam Reports Fourth Quarter and Full Year 2024 Results -March 13, 2025 at 05:31 pm EDT - Marketscreener.com
Heartbeam Inc reports results for the quarter ended December 31Earnings Summary - TradingView
HeartBeam Reports Fourth Quarter and Full Year 2024 Results - Business Wire
HeartBeam (NASDAQ: BEAT) To Present At Upcoming Investor And Industry Conferences - Barchart
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025 - The Bakersfield Californian
Meet HeartBeam Executives: Key Investment Conferences Set for California Next Month - StockTitan
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time - The Bakersfield Californian
HeartBeam (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M - The Globe and Mail
HeartBeam closes underwriter’s over-allotment option for PO - Medical Buyer
HeartBeam Raises $11.5M: What This Capital Injection Means for Its Commercial Launch Timeline - StockTitan
Heartbeam CFO Tim Cruickshank buys $29,999 in company stock - Investing.com India
Heartbeam director Richard Ferrari buys $50,000 in stock By Investing.com - Investing.com Australia
Heartbeam director Richard Ferrari buys $50,000 in stock - Investing.com India
Heartbeam CFO Tim Cruickshank buys $29,999 in company stock By Investing.com - Investing.com Nigeria
HeartBeam announces pricing of UPO - Medical Buyer
HeartBeam submits 510(k) application to FDA for ECG software - MSN
HeartBeam sets price for $10 million stock offering - MSN
HeartBeam prices public offering of 5.88M shares; shares down - MSN
HeartBeam Secures Major Funding: FDA-Cleared Cardiac Innovation Gets $10M Boost - StockTitan
US Penny Stocks Spotlight: HeartBeam And Two More Standout Picks - Yahoo Finance
HeartBeam (NASDAQ: BEAT) Submits FDA Application for 12-Lead ECG Synthesis Software - The Globe and Mail
HeartBeam seeks FDA nod for ECG synthesis software - MSN
HeartBeam Submits 12-Lead ECG Synthesis Software to FDA - MPO-mag
BEATHeartbeam, Inc. Latest Stock News & Market Updates - StockTitan
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software - Business Wire
This Tiny Medical Device Could Transform Heart Attack DetectionHeartBeam's Game-Changing FDA Filing - Stock Titan
Blaize Appoints Yoshiaki Fujimori and George de Urioste to Board of Directors - Business Wire
JP Morgan Chase & Company (JPM-N) QuotePress Release - The Globe and Mail
HeartBeam (NASDAQ: BEAT) To Present At JP Morgan 2025 Annual Healthcare Conference - Barchart
Heartbeam Inc (BEAT-Q) QuotePress Release - The Globe and Mail
HeartBeam to Showcase FDA-Cleared Revolutionary Heart Monitor at JP Morgan Healthcare Conference - StockTitan
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference - Business Wire
HeartBeam’s arrhythmia assessment system gains FDA 510(k) clearance - Yahoo! Voices
Heartbeam Inc Stock (BEAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
2.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):